Previously, we suggested targeting melanin, an intracellular antigen which becomes available for the antibody binding in the leaky or dying tumor cells, with a radiolabeled murine IgM pre-clinically and in Phase I clinical trial in patients with metastatic melanoma [22,23]. The gene discussed is CD40LG; the disease is neoplasm.